Inicio Blog Página 10

[podcast] Prof. Graham Beastall: IFCC Working Group on Personal Support

0

Doctor Graham Beastall (BSc, PhD, CSci, EurClinChem, FRCPath, FRCP, CBE), currently serves as professional adviser on laboratory medicine for the Department of Health in the UK. Immediately prior to becoming IFCC President he was the Clinical Lead for the multi-site network Department of Clinical Biochemistry in North Glasgow, Scotland, United Kingdom (UK).

He received his BSc and PhD degrees from the University of Liverpool in the late 1960s. After postdoctoral study he moved to Glasgow in 1972 as a University lecturer and became an employee in the National Health Service (NHS) as the rapid expansion of clinical chemistry practice required experienced leaders. He has specialized in biochemical endocrinology and in 1979 he formed and led the Scottish specialist endocrine laboratory based at Glasgow Royal Infirmary

Prof. Graham Beastall presents the IFCC Working Group on Personal Support: WG PS

Listado de emisiones anteriores

No se encontraron entradas.

[podcast] Prof. Garry John: European trial HbA1c

0

Professor Garry John

Speciality: Clinical Biochemistry

Special clinical interests: Diabetes; Endocrinology; Lipids

Research interests: Glycation; Pathogenesis of Diabetes; Alcohol abuse

Current membership(s) of professional National and Regional bodies: Royal College of Pathologists; Association of Clinical Biochemists; American Association for Clinical Chemistry; European Association for the Study of Diabetes; Diabetes UK; Heart UK.

[podcast] Prof. Mark Hutchinson & Ms. Krystal Iacopetta: Vitamin D is not going to be the miracle ‘sunshine tablet’ solution for brain-disorders

0

Professor Mark Hutchinson, ARC Research Fellow, School of Medical Sciences and irector, ARC Centre of Excellence for Nanoscale BioPhotonics. The University of Adelaide.

Bio: http://www.adelaide.edu.au/directory/mark.hutchinson

Ms. Krystal Iacopetta, PhD student. Adelaide Medical School, The University of Adelaide.

[podcast] James H. Nichols: The Journal of Applied Laboratory Medicine

0

Dr. Nichols is Professor of Pathology at Tufts University School of Medicine and Medical Director, Clinical Chemistry for Baystate Health in Springfield, MA. He received his B.A. in General Biology/Premedicine from Revelle College, University of California at San Diego. He went on to complete a Masters and Doctorate in Biochemistry from the University of Illinois, Urbana-Champaign. Dr. Nichols was a fellow in the Postdoctoral Training Program in Clinical Chemistry at the Mayo Clinic, Rochester, MN. He is board certified in both Clinical Chemistry and Toxicological Chemistry by the American Board of Clinical Chemistry.

Launch of the new journal, The Journal of Applied Laboratory Medicine: An AACC Publication

New cervical cancer screening guidelines recommend HPV testing alone

0

The USPSTF Recommendation Statement, published today in the Journal of the American Medical Association, assigns a grade of “A”—indicating the service is recommended and there is a “high certainty that the net benefit is substantial”—for high-risk HPV testing every five years for women 30 to 65. It also retains prior recommendations for Pap testing alone every three years for women 21 to 65 and cotesting (Pap plus HPV) for women 30-65. The task force noted that it found convincing evidence that these screening practices substantially reduce the incidence of cervical cancer and mortality.

“This action by the USPSTF to recommend HPV testing alone represents a milestone in women’s health, because it shows that U.S. clinical guidelines are catching up to science and to the rest of the world,” said Lee Shulman, MD, FACMG, FACOG, professor in obstetrics and gynecology and chief of the Division of Clinical Genetics at the Feinberg School of Medicine at Northwestern University. “Multiple studies have shown that you get the same benefit from HPV testing alone that you do from cotesting, but at a lower cost. This Recommendation moves the U.S. closer to common ground with all of the major countries in Europe and Australia who began implementing primary HPV screening programs some time ago.”

Several leading medical societies in the U.S., including the American Congress of Obstetricians and Gynecologists (ACOG), currently support the use of an HPV test approved by the FDA for first-line primary screening (i.e., without an accompanying Pap test) in women age 25 and older, in conjunction with an FDA-approved screening algorithm. When the U.S. Food and Drug Administration (FDA) approved the first HPV test for primary screening in 2014, it included in its approval a testing algorithm that directed healthcare providers to follow a specific protocol for patient management, which included a role for Pap testing and colposcopy as follow-up tests for certain types of HPV test results.

“Using HPV DNA testing as the primary screening test and utilizing the Pap test to triage women who are positive for HPV enables healthcare providers to utilize the two tests in their most appropriate roles to achieve the best cancer prevention strategy,” said Alan Wright, MD, MPH, chief medical officer at Roche Diagnostics. “By using the more sensitive test—HPV—for first-line screening, caregivers can safely send home women who test negative for high-risk HPV. We’re glad to see the USPSTF incorporate the latest science to help healthcare professionals provide the best care for patients and advance the effort to prevent cervical cancer.”

The USPSTF Recommendation Statement, which was circulated in draft form for public comment in September 2017, replaces the 2012 Recommendation Statement.

About US Preventive Services Task Force Recommendations

Created in 1984, the U.S. Preventive Services Task Force is an independent, volunteer panel of national experts in prevention and evidence-based medicine. The Task Force works to improve the health of all Americans by making evidence-based recommendations about clinical preventive services such as screenings, counseling services, and preventive medications. Their recommendations are based on a rigorous review of existing peer-reviewed evidence and are intended to help primary care clinicians and patients decide together whether a preventive service is right for a patient’s needs.

Since 1998, the Agency for Healthcare Research and Quality (AHRQ) has been authorized by the U.S. Congress to convene the Task Force and to provide ongoing scientific, administrative, and dissemination support.

About Primary HPV Testing

The U.S. Food and Drug Administration (FDA) approved the first HPV test (cobas HPV Test) for first-line primary cervical cancer screening of women 25 and older in March of 2014, following a unanimous recommendation from the independent Microbiology Devices Panel of the FDA’s Medical Devices Advisory Committee. The cobas HPV Test had been initially approved by the FDA in 2011 for use in screening women 21 and older with unclear Pap test results and for co-testing with a Pap test in women 30 and older. Currently utilized by more than 250 labs in the U.S., it is the only test approved in the U.S. for all three HPV testing options supported by major medical societies.

About Human Papillomavirus and Cervical Cancer

Persistent infection with high-risk Human Papillomavirus (HPV) is the principal cause of cervical cancer in women, with HPV implicated in greater than 99 percent of cervical cancers worldwide. The National Cancer Institute estimates that there will be more than 13,000 new cases of cervical cancer and more than 4,000 deaths due to the disease in the United States in 2018. The World Health Organization estimates there are more than 500,000 new cases of cervical cancer annually.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com or usdiagnostics.roche.com.

All trademarks mentioned in this release are protected by law.

Source: prnewswire.com

When Endocrine Test Results Don’t Make Sense

0

Fortunately, Tuesday’s morning session, “Clinical Assay Issues: What Endocrinologists Will Ask You,” helped equip laboratorians to answer three of the most common laboratory queries facing endocrinologists. Mark Gurnell, MBBS, PhD, spoke about the difficulties in interpreting thyroid function tests when the results are discordant or when the results contradict the clinical picture. He reminded attendees to take a systematic approach to troubleshooting and provided five illustrative clinical vignettes of cases that presented to his laboratory.

First, look at the clinical setting and determine if there are any potential confounders such as pregnancy, non-thyroidal illness or medications such thyroxine, amiodarone, heparin, or glucocorticoids. Once these have been eliminated, the next step is to consider laboratory artefacts and assay interferences. Finally, once these have been excluded, consider genetic or acquired disorders.

In the second presentation, Nikola Baumann, PhD, spoke about how biotin can sometimes interfere with lab measurements. It is essential for clinical laboratorians to know not only how assays in their lab work, but also how to explain potential interferences to clinicians.

Biotin supplements (also known as vitamin B7) have been promoted for thickening hair, strengthening nails, and improving skin, leading to an increase in their use. Previously, high-dose biotin therapy was confined to patients with biotinidase deficiency, certain forms of alopecia, or multiple sclerosis. Now the popularity of biotin supplement use has also led to an increase in reported cases of biotin interferences, increasing the potential for misdiagnoses.

Based on a survey of nearly 200 patients, Baumann and her colleagues discovered that only 8% of outpatients were aware that they were taking biotin supplements. Biotin interference can affect an extensive range of assays. These include assays used to diagnose and monitor malignancies (Tg, calcitonin, gastrin), thyroid disorders (TSH, free T4, total T4, free T3, total T3), bone and calcium homeostasis (PTH, 25-OH vitamin D), reproductive hormones (progesterone, LH, FSH, estradiol, DHEAS, testosterone, beta-hCG), anemia (ferritin), and cardiac markers (NT-pro-BNP, troponin).

Biotin interference can happen because most immunoassay manufacturers rely on biotin-streptavidin capture in their assays. Biotin interference can cause a falsely increased result in competitive assays and a falsely low result in sandwich assays. A complicating factor is that the concentration of biotin that causes interferences is assay-dependent.

To identify biotin interference, Baumann suggested that labs can perform serial dilution checks to see if they are linear. Labs can also test the sample on a platform that does not use biotin-streptavidin capture. Most manufacturers suggest that patients taking biotin supplements wait 8 hours before having laboratory testing, however, according to Baumann, “we have learned some additional lessons on this journey.”

For instance, biotin is not readily cleared in patients with impaired renal function, and biotin concentrations that affect assays can still be observed in these patients up to 72 hours post-consumption. In addition, the majority of cases reviewed did not list biotin supplements in the electronic medication list.

The third speaker, David Sacks, MB ChB, FRCPath, explained how factors independent of glucose concentration changes can alter HbA1c. HbA1c reflects the estimated average glucose concentrations over approximately 8-12 weeks and is used by endocrinologists to diagnose diabetes, monitor long-term glucose control, alter medication dosages in diabetic patients and measure the risk of cardiovascular complications in diabetic patients. Hemoglobin variants, elevations of hemoglobin F, and renal failure all can cause analytical interferences.

When a lab suspects one of these, Sachs explained that testing by an alternative method can often provide an accurate result. For conditions that affect the lifespan of red blood cells—for example, chronic renal failure, hereditary spherocytosis, hemolytic anemia or some medications—or when blood transfusions or blood loss occur, the lab should use alternate measurements such as fructosamine of glycated albumin.

Source: aacc.org

The Role of Point-of-Care Testing in a Value-Based Healthcare Landscape: 27th AACC International CPOCT Symposium

0

This event is presented in collaboration with the AACC Critical and Point-of-Care Testing Division and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).

Plan to join us for the 27th International CPOCT Symposium, which will focus on the current and future role of point-of-care testing in a healthcare environment with an emphasis on value and quality of care.

You will learn how point-of-care testing contributes to healthcare value through faster result turnaround time, lower testing costs, improved patient linkage to care and outcomes, and greater satisfaction for patients and healthcare providers.

Session topics will address public health and disease prevention, diagnosis and monitoring disease for the critically ill, at-home patient self-management, direct-to-consumer testing, and new/emerging technologies.

Registration fee includes conference materials, breakfasts, lunches, and evening receptions.

Program

Photos and Credentials of Speakers

*Program is subject to change

Wednesday, September 26, 2018

  • 5:30 – 6:30 pm WELCOME RECEPTION

Thursday, September 27, 2018

  • 8:30 – 8:45 am OPENING REMARKS. Leslie Donato, PhD (Committee chair); Mayo Clinic, Rochester, MN
  • 8:45 – 9:20 am KEYNOTE PRESENTATION. The Value of POCT in Patient Diagnosis and Improved Clinical Outcomes. Keynote Speaker: Danielle Freedman, MB BS; Luton & Dunstable University Hospital, Luton, United Kingdom
  • 9:20 – 9:30 am Q&A with Dr. Freedman

SESSION 1: POCT IN PUBLIC HEALTH AND DISEASE PREVENTION. Moderator: Nichole Korpi-Steiner, PhD; University of North Carolina Hospitals

  • 9:30 – 9:35 am Moderator introduction to session
  • 9:35 – 10:05 am HIV testing and Linkage to Care
    Debbie Mohammed, PhD, MS, MPH; William Paterson University, Wayne, NJ
  • 10:05 – 10:10 am Q&A with Dr. Mohammed
  • 10:10 – 10:35 am BREAK – NETWORKING AND VISIT EXHIBITORS
  • 10:35 – 11:05 am Efficacy of Child-Parent Familial Cholesterol Screening in Primary Care
    Amy Peterson, MD; University of Wisconsin School of Medicine and Public Health
  • 11:05 – 11:10 am Q&A with Speaker
  • 11:10 – 11:40 am Lead Screening: Effectiveness and Analytical Considerations
    Douglas Stickle, PhD; Jefferson University Hospital, Philadelphia, PA
  • 11:40 – 11:45 am Q&A with Dr. Stickle
  • 11:45 – 11:55 am Point of Care Creatinine to Assist Clinical Decision Making in Suspected Sepsis in the Community.
    Dimitris Poulikakos, MD; Salford Royal NHS Foundation Trust
  • 11:55 am – 12:00 pm Q&A with Dimitrios Poulikakos
  • 12:15 – 1:45 pm LUNCH AND VISIT EXHIBITORS

SESSION 2: DISEASE DIAGNOSIS AND MONITORING FOR THE CRITICALLY ILL
Moderator: Brad Karon, MD, PhD; Mayo Clinic, Rochester, MN

  • 1:45 – 1:50 pm Moderator introduction to session
  • 1:50 – 2:20 pm The Benefits and Challenges of Point of Care Testing for Respiratory Tract Infection. Leslie Wolf, PhD; Louisville Metro Public Health and Wellness Laboratory, Louisville, KY
  • 2:20 – 2:25 pm Q&A with Dr. Wolf
  • 2:25 – 2:55 pm Hemostasis Testing for Liver Transplant. Antonio Leon-Justel, MD; University Hospital, Institute of Biomedicine of Seville, Spain
  • 2:55 – 3:00 pm Q&A with Dr. Leon-Justel
  • 3:00 – 3:25 pm BREAK – NETWORKING AND VISIT EXHIBITORS
  • 3:25 – 3:55 pm Update on biomarkers for acute kidney injury. Chirag Parikh, MD, PhD; Johns Hopkins University Medical Institutions, Baltimore, MD
  • 3:55 – 4:00 pm Q&A with Dr. Parikh
  • 4:00 – 4:10 pm Clinical Impact of an Autocorrecting Blood Glucose Monitoring System in the Severely Burned Adult Population: A Pre- and Post-Implementation Comparison Study. Nam Tran, MS, MAS, PhD; University of California, Davis, Davis, CA
  • 4:10 – 4:15 pm Q&A with Dr. Tran
  • 4:15 – 4:25 pm Implementation and Ongoing Support of POCT in the World’s Only Stroke Ambulance for Rural Stroke Care. Anna Füezéry, PhD; Royal Alexandra Hospital, Edmonton, Alberta, Canada
  • 4:25 – 4:30 pm Q&A with Dr. Füezéry
  • 4:30 – 5:30 pm RECEPTION WITH POSTER VIEWING AND VISIT EXHIBITORS

Friday, September 28, 2018

8:30 – 9:30 am CORPORATE SUPPORTER PRESENTATIONS (Industry Viewpoints)

SESSION 3: POCT IN AT-HOME PATIENT SELF-MANAGEMENT FOR ACUTE AND CHRONIC DISEASES. Moderator: Rob Nerenz, PhD; Dartmouth-Hitchcock Medical Center, Hanover, NH

  • 9:30 – 9:35 am Moderator introduction to session
  • 9:35 – 10:05 am Continuous Glucose Monitors – Improved Outcomes, Challenges for Laboratorians. Timothy Bailey, MD; Advanced Metabolic Care and Research Institute, University of California, San Diego, CA
  • 10:05 – 10:10 am Q&A with Dr. Bailey
  • 10:10 – 10:40 am TBD
    Speaker TBD
  • 10:35 – 10:45 am Q&A withTBD
  • 10:45 – 11:10 am BREAK – NETWORKING AND VISIT EXHIBITORS
  • 11:10 – 11:40 am Monitoring Creatinine Following Renal Transplant. Celine van Lint, MSc; Leiden University Medical Center, Netherlands
  • 11:40 – 11:45 am Q&A with Dr. van Lint
  • 11:45 – 1:30 pm LUNCH AND VISIT EXHIBITORS

SESSION 4: POCT AND DIRECT TO CONSUMER TESTING. Moderator: T. Scott Isbell, PhD; St. Louis University School of Medicine, MO

  • 1:30 – 1:35 pm Moderator introduction to session
  • 1:35 – 1:55 pm Digital Health and the Engaged Patient. David Grenache, PhD; TriCore Reference Laboratories, NM
  • 1:55 – 2:15 pm Legal Perspectives on Direct to Consumer Testing. Timothy Allen, MD, JD; University of Mississippi, Jackson, MS
  • 2:15 – 2:35 pm Ethical Perspectives on Direct to Consumer Testing. Anita Ho, PhD, MPH; The University of British Columbia, Vancouver, Canada
  • 2:35 – 3:05 pm Panel Discussion and Q&A with Session 4 speakers
  • 3:05 – 3:35 pm NETWORKING AND VISIT EXHIBITORS
  • 5:30 – 7:30 pm AWARDS RECEPTION at the National Press Club

Saturday, September 29, 2018

SESSION 5: NEW AND EMERGING POCT TECHNOLOGIES. Moderator: Brenda Suh-Lailam, PhD; Lurie Children’s Hospital, Chicago, IL

  • 8:30 – 8:35 am Moderator introduction to session
  • 8:35 – 9:05 am Ambient Ionization Mass Spectrometry for Point-of-Care Diagnostics. Graham Cooks, PhD; Purdue University, West Lafayette, IN
  • 9:05 – 9:15 am Q&A with Dr. Cooks
  • 9:15 – 9:45 am Genetic Testing Made Possible with a Smartphone
    Syed Hashsham, PhD; Michigan State University, Lansing, MI
  • 9:45 – 9:55 am Q&A with Dr. Hashsham
  • 9:55 – 10:15 am BREAK – NETWORKING and VISIT EXHIBITORS
  • 10:15 – 10:45 am Sweat Analysis using Microfluidics. John Rogers, PhD; Northwestern University School of Engineering, Chicago, IL
  • 10:45 – 10:55 am Q&A with Dr. Rogers
  • 10:55 – 11:05 am Reducing Hospital Length of Stay and Readmission Rates in Surgical Inpatients with Diabetes Mellitus Through Improved Glycaemic Control Using an Automated Glucose System.
    Irene Kopp, NP/CDE; Nepean Diabetes Service, Penrith NSW, Australia
  • 11:05 – 11:10 am Q&A with Irene Kopp
  • 11:10 – 11:20 am CLOSING REMARKS. Leslie Donato, PhD (Committee chair); Mayo Clinic, Rochester, MN
  • 11:20 – 12:45 SPECIAL PRESENTATION FROM THE INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY (IFCC) Glucose monitoring in critically ill patients; what do we need to know? An overview of the IFCC report: “How Should Glucose Meters be Evaluated for Critical Care?” Cynthia Bowman, MD; Baystate Health, Springfield, MA. Sean Cunningham, PhD, EuSpLM; Dublin, Ireland

[podcast] David Grenache: 70th AACC Annual Scientific Meeting & Clinical Lab Expo

0

Dr. Grenache is an associate professor of pathology at the University of Utah Health Sciences Center and the medical director of the Special Chemistry laboratory at ARUP Laboratories in Salt Lake City, UT. He received his BA in biology and BS in medical technology from the Massachusetts College of Liberal Arts in North Adams, MA, and his PhD in biomedical sciences from Worcester Polytechnic Institute in Worcester, MA.

Dr. Grenache completed his postdoctoral training in clinical chemistry at Washington University School of Medicine in St. Louis, MO. He is board certified by the American Board of Clinical Chemistry and is a fellow in the National Academy of Clinical Biochemistry. His research interests are in the areas of reproductive biochemistry, clinical applications of soluble tumor markers, and emerging biomarkers of disease.

The Role of Point-of-Care Testing in a Value-Based Healthcare Landscape: 27th AACC International CPOCT Symposium

0

Credit: 11.0 ACCENT Credits and 11.0 CME Credits

Date: SEP.26.2018 5:30 PM – SEP.29.2018 12:30 PM

Location: Washington, DC, USA

Price: $775.00Member Price: $540.00

Plan to join us for the 27th International CPOCT Symposium, which will focus on the current and future role of point-of-care testing in a healthcare environment with an emphasis on value and quality of care.

You will learn how point-of-care testing contributes to healthcare value through faster result turnaround time, lower testing costs, improved patient linkage to care and outcomes, and greater satisfaction for patients and healthcare providers.

Session topics will address public health and disease prevention, diagnosis and monitoring disease for the critically ill, at-home patient self-management, direct-to-consumer testing, and new/emerging technologies

Register -> www.aacc.org/the-role-of-point-of-care-testing-in-a-value-based-healthcare-landscape

No more information is available on infobioquimica.org.
For further requests, you can contact the organizers of the event.

Agenda

       

Radio El Microscopio

Ze Xiong

Últimas notas publicadas